LeMaitre Vascular
Market Cap
US$906.8m
Last Updated
2021/01/19 23:20 UTC
Data Sources
Company Financials +
Executive Summary
LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. More Details
Snowflake Analysis
Excellent balance sheet second-rate dividend payer.
Similar Companies
Share Price & News
How has LeMaitre Vascular's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: LMAT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: LMAT's weekly volatility (6%) has been stable over the past year.
Market Performance
7 Day Return
7.1%
LMAT
0.6%
US Medical Equipment
0.3%
US Market
1 Year Return
20.7%
LMAT
20.0%
US Medical Equipment
21.1%
US Market
Return vs Industry: LMAT matched the US Medical Equipment industry which returned 20% over the past year.
Return vs Market: LMAT exceeded the US Market which returned 19.5% over the past year.
Shareholder returns
| LMAT | Industry | Market | |
|---|---|---|---|
| 7 Day | 7.1% | 0.6% | 0.3% |
| 30 Day | 17.5% | 3.3% | 3.3% |
| 90 Day | 41.8% | 9.9% | 14.2% |
| 1 Year | 22.2%20.7% | 21.0%20.0% | 23.8%21.1% |
| 3 Year | 35.4%31.1% | 70.7%66.4% | 45.0%35.4% |
| 5 Year | 215.6%200.2% | 169.2%149.1% | 127.7%102.3% |
Long-Term Price Volatility Vs. Market
How volatile is LeMaitre Vascular's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 days ago | Simply Wall St
Are Strong Financial Prospects The Force That Is Driving The Momentum In LeMaitre Vascular, Inc.'s NASDAQ:LMAT) Stock?2 weeks ago | Simply Wall St
Is There Now An Opportunity In LeMaitre Vascular, Inc. (NASDAQ:LMAT)?4 weeks ago | Simply Wall St
What Did LeMaitre Vascular's (NASDAQ:LMAT) CEO Take Home Last Year?Valuation
Is LeMaitre Vascular undervalued compared to its fair value and its price relative to the market?
47.82x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: LMAT ($44.58) is trading above our estimate of fair value ($42.06)
Significantly Below Fair Value: LMAT is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: LMAT is good value based on its PE Ratio (47.8x) compared to the US Medical Equipment industry average (54.1x).
PE vs Market: LMAT is poor value based on its PE Ratio (47.8x) compared to the US market (21x).
Price to Earnings Growth Ratio
PEG Ratio: LMAT is poor value based on its PEG Ratio (3.4x)
Price to Book Ratio
PB vs Industry: LMAT is overvalued based on its PB Ratio (5.6x) compared to the US Medical Equipment industry average (5.1x).
Next Steps
Future Growth
How is LeMaitre Vascular forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
14.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LMAT's forecast earnings growth (14.1% per year) is above the savings rate (2%).
Earnings vs Market: LMAT's earnings (14.1% per year) are forecast to grow slower than the US market (21.6% per year).
High Growth Earnings: LMAT's earnings are forecast to grow, but not significantly.
Revenue vs Market: LMAT's revenue (9.7% per year) is forecast to grow slower than the US market (10.3% per year).
High Growth Revenue: LMAT's revenue (9.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: LMAT's Return on Equity is forecast to be low in 3 years time (12.3%).
Next Steps
Past Performance
How has LeMaitre Vascular performed over the past 5 years?
16.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: LMAT has high quality earnings.
Growing Profit Margin: LMAT's current net profit margins (15.4%) are lower than last year (16.7%).
Past Earnings Growth Analysis
Earnings Trend: LMAT's earnings have grown by 16.9% per year over the past 5 years.
Accelerating Growth: LMAT's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: LMAT had negative earnings growth (-2.7%) over the past year, making it difficult to compare to the Medical Equipment industry average (-0.3%).
Return on Equity
High ROE: LMAT's Return on Equity (11.7%) is considered low.
Next Steps
Financial Health
How is LeMaitre Vascular's financial position?
Financial Position Analysis
Short Term Liabilities: LMAT's short term assets ($102.3M) exceed its short term liabilities ($44.4M).
Long Term Liabilities: LMAT's short term assets ($102.3M) exceed its long term liabilities ($56.1M).
Debt to Equity History and Analysis
Debt Level: LMAT's debt to equity ratio (36.9%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if LMAT's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: LMAT's debt is well covered by operating cash flow (44.1%).
Interest Coverage: LMAT's interest payments on its debt are well covered by EBIT (60.1x coverage).
Balance Sheet
Next Steps
Dividend
What is LeMaitre Vascular current dividend yield, its reliability and sustainability?
0.85%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: LMAT's dividend (0.85%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.39%).
High Dividend: LMAT's dividend (0.85%) is low compared to the top 25% of dividend payers in the US market (3.85%).
Stability and Growth of Payments
Stable Dividend: LMAT's dividends per share have been stable in the past 10 years.
Growing Dividend: LMAT's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (39.7%), LMAT's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
14.8yrs
Average management tenure
CEO
George LeMaitre (55 yo)
28.58yrs
Tenure
US$1,397,743
Compensation
Mr. George W. LeMaitre has been Chief Executive Officer of Lemaitre Vascular, Inc. since June 1992 and has been its Chairman since 2004. Mr. LeMaitre served as the President of Lemaitre Vascular from June ...
CEO Compensation Analysis
Compensation vs Market: George's total compensation ($USD1.40M) is below average for companies of similar size in the US market ($USD2.40M).
Compensation vs Earnings: George's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 28.58yrs | US$1.40m | 13.87% $ 125.8m | |
| President & Director | 19.67yrs | US$746.83k | 0.24% $ 2.2m | |
| CFO, Treasurer | 4.25yrs | US$685.98k | 0.0031% $ 28.0k | |
| Senior Vice President of Operations | 16yrs | US$471.89k | 0.0026% $ 23.3k | |
| Founder and Chairman of Scientific Advisory Board | no data | US$138.40k | no data | |
| Senior VP & General Counsel | 7yrs | no data | no data | |
| Vice President of Marketing | 18yrs | no data | no data | |
| Senior Vice President of Clinical | 8yrs | no data | no data |
14.8yrs
Average Tenure
52yo
Average Age
Experienced Management: LMAT's management team is seasoned and experienced (14.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 28.58yrs | US$1.40m | 13.87% $ 125.8m | |
| President & Director | 19.67yrs | US$746.83k | 0.24% $ 2.2m | |
| CFO, Treasurer | 4.25yrs | US$685.98k | 0.0031% $ 28.0k | |
| Founder and Chairman of Scientific Advisory Board | no data | US$138.40k | no data | |
| Independent Director | 18yrs | US$123.00k | 0.041% $ 371.4k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 12.33yrs | US$128.00k | 0.27% $ 2.5m |
17.0yrs
Average Tenure
59.5yo
Average Age
Experienced Board: LMAT's board of directors are seasoned and experienced ( 17 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: LMAT insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
LeMaitre Vascular, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: LeMaitre Vascular, Inc.
- Ticker: LMAT
- Exchange: NasdaqGM
- Founded: 1983
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$906.846m
- Shares outstanding: 20.34m
- Website: https://www.lemaitre.com
Number of Employees
Location
- LeMaitre Vascular, Inc.
- 63 Second Avenue
- Burlington
- Massachusetts
- 1803
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| LMAT | NasdaqGM (Nasdaq Global Market) | Yes | Common Stock | US | USD | Oct 2006 |
| LHU | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Oct 2006 |
Biography
LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/19 23:20 |
| End of Day Share Price | 2021/01/19 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.